Triple-positive profile may flag adverse prostate cancer pathology
A combination of PSA density, MRI, and PSMA PET findings identified a small subgroup with adverse pathology, supporting further study of biopsy-sparing pathways.
By
Andrea Surnit
September 8, 2026
Clinical Scorecard: Triple-positive profile may flag adverse prostate cancer pathology
At a Glance
Category Detail
Condition Prostate Cancer
Key Mechanisms Combination of prostate-specific antigen density, multiparametric MRI, and PSMA PET/CT findings
Target Population Patients undergoing radical prostatectomy for prostate cancer
Care Setting Retrospective evaluation in a single-center study
Key Highlights
60% of patients had adverse pathology at radical prostatectomy. Adverse pathology rates increased with higher PSAD and PI-RADS scores. The triple-positive profile showed 100% specificity and positive predictive value. Only 22 patients met all three criteria for the triple-positive profile. The study suggests further investigation into biopsy-sparing strategies.
Guideline-Based Recommendations
Diagnosis
Evaluate prostate-specific antigen density, mpMRI, and PSMA PET/CT findings.
Management
Consider the triple-positive profile for prospective studies of biopsy omission.
Monitoring & Follow-up
Monitor patients with PSAD, PI-RADS, and SUVmax findings.
Risks
Potential for selection bias and unmeasured confounding due to retrospective design.
Patient & Prescribing Data
413 patients who underwent radical prostatectomy between December 2015 and December 2024.
Biopsy provides important histologic information for treatment planning.
Clinical Best Practices
Use combined clinical and imaging predictors for assessing adverse pathology. External validation of proposed criteria is warranted before adoption.
Related Resources & Content